Quarterly report pursuant to Section 13 or 15(d)

Acquisition of Pelican Therapeutics (Schedule of Pro Forma Financial Information for Acquisition) (Details)

v3.10.0.1
Acquisition of Pelican Therapeutics (Schedule of Pro Forma Financial Information for Acquisition) (Details) - USD ($)
9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Business Combinations [Abstract]    
Revenue $ 3,735,713 $ 906,313
Net loss (11,463,927) (9,444,913)
Net loss: Non-controlling interest (668,219) (422,513)
Net loss attributable to Heat Biologics, Inc. $ (10,795,708) $ (9,022,400)
Net loss per share attributable to Heat Biologics, Inc.-basic and diluted $ (0.75) $ (2.65)